Genscript doesn’t equal to CGT CXO. Its core competitiveness is gene synthesis,which has larger potential than expected. However,there're concerns about the management. Short-term trade is recommended
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.